Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

STL DIAGNOSTIC LLC

NPI: 1003406232 · SAINT LOUIS, MO 63109 · Clinical Medical Laboratory · NPI assigned 01/21/2021

$320K
Total Medicaid Paid
5,355
Total Claims
4,747
Beneficiary Records
6
Codes Billed
2021-09
First Month
2023-10
Last Month

Provider Details

Authorized OfficialHAIDER, SYED (OWNER)
NPI Enumeration Date01/21/2021

Related Entities

Other providers sharing the same authorized official: HAIDER, SYED

ProviderCityStateTotal Paid
LABTEST LLC SAINT LOUIS MO $4.17M
AUTISM AND BEHAVIORAL SPECTRUM LLC CHESTERFIELD MO $2.04M
NEWBORN AND PEDIATRIC CARE OF WEST HOUSTON PLLC KATY TX $570K
CYBER DIAGNOSTIC MEDICINE LLC FLORISSANT MO $198K
LABTEST LLC HOUSTON TX $74K
SULTANA'S MEDICAL, LLC BUFFALO NY $58K
BELLEVILLE DIAGNOSTIC CENTER, LLC BELLEVILLE IL $2K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2021 679 $39K
2022 1,974 $116K
2023 2,702 $165K

Billing Codes

CodeDescriptionClaimsBene. RecordsTotal Paid
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 2,978 2,700 $230K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,908 1,625 $72K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 191 172 $12K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 177 159 $4K
G2024 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source 61 54 $967.48
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 40 37 $914.94